Michael Termer1, Christophe Carola2, Andrew Salazar2, Cornelia M Keck3, Juergen Hemberger4, Joerg von Hagen5. 1. Department of Pharmaceutics and Biopharmaceutics, Philipps-University of Marburg, Marburg, Germany. Electronic address: michael.termer1@gmail.com. 2. Merck KGaA, BU Performance Materials, Darmstadt, Germany. 3. Department of Pharmaceutics and Biopharmaceutics, Philipps-University of Marburg, Marburg, Germany. 4. Department of Life Science Engineering, Institute for Biochemical Engineering & Analytics, University of Applied Sciences, Giessen, Germany. 5. Department of Life Science Engineering, Institute for Biochemical Engineering & Analytics, University of Applied Sciences, Giessen, Germany; Merck KGaA, BU Performance Materials, Darmstadt, Germany.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Waltheria Indica L. is traditionally used in Africa, South America and Hawaii to treat pain, anemia, diarrhea, epilepsy and inflammatory related diseases. AIM OF THE STUDY: This study aimed to identify extraction parameters to maximize tiliroside yield and to quantitative secondary metabolite composition of Waltheria Indica under various extraction conditions. The extracts were tested for COX-2 inhibition and their activity correlated with the type and quantity of the secondary metabolites. Insight was gained about how extraction parameters influence the extract composition and thus the COX-2 enzymatic inhibitory activity. MATERIALS AND METHODS: Powdered leaves of Waltheria Indica were extracted using water, methanol, ethyl acetate and ethanol at different temperatures. Tiliroside was identified by HPLC-HRMS n and quantified using a tiliroside standard. The compound groups of the secondary metabolites were quantified by spectrometric methods. Inhibitory potential of different Waltheria extracts against the COX-2 enzyme was determined using a fluorometric COX-2 inhibition assay. RESULTS: The molecule, tiliroside, exhibited a COX-2 inhibition of 10.4% starting at a concentration of 15 μM and increased in a dose dependent manner up to 51.2% at 150 μM. The ethanolic extract at 30 °C and the ethyl acetate extract at 90 °C inhibited COX-2 with 37.7% and 38.9%, while the methanolic and aqueous extract showed a lower inhibition of 21.9% and 9.2% respectively. The results concerning phenol, alkaloid and tiliroside concentration in the extracts showed no dependence on COX-2 inhibition. The extracts demonstrated a direct correlation of COX-2 inhibitory activity with their triterpenoid-/steroidal-saponin concentration. COX-2 inhibition increased linearly with the concentration of the saponins. CONCLUSION: The data suggest that Waltheria Indica extracts inhibit the key inflammatory enzyme, COX-2, as a function of triterpenoid- and steroidal-saponin concentration and support the known efficacy of extracted Waltheria Indica leaves as a traditional treatment against inflammation related diseases.
ETHNOPHARMACOLOGICAL RELEVANCE: Waltheria Indica L. is traditionally used in Africa, South America and Hawaii to treat pain, anemia, diarrhea, epilepsy and inflammatory related diseases. AIM OF THE STUDY: This study aimed to identify extraction parameters to maximize tiliroside yield and to quantitative secondary metabolite composition of Waltheria Indica under various extraction conditions. The extracts were tested for COX-2 inhibition and their activity correlated with the type and quantity of the secondary metabolites. Insight was gained about how extraction parameters influence the extract composition and thus the COX-2 enzymatic inhibitory activity. MATERIALS AND METHODS: Powdered leaves of Waltheria Indica were extracted using water, methanol, ethyl acetate and ethanol at different temperatures. Tiliroside was identified by HPLC-HRMS n and quantified using a tiliroside standard. The compound groups of the secondary metabolites were quantified by spectrometric methods. Inhibitory potential of different Waltheria extracts against the COX-2 enzyme was determined using a fluorometric COX-2 inhibition assay. RESULTS: The molecule, tiliroside, exhibited a COX-2 inhibition of 10.4% starting at a concentration of 15 μM and increased in a dose dependent manner up to 51.2% at 150 μM. The ethanolic extract at 30 °C and the ethyl acetate extract at 90 °C inhibited COX-2 with 37.7% and 38.9%, while the methanolic and aqueous extract showed a lower inhibition of 21.9% and 9.2% respectively. The results concerning phenol, alkaloid and tiliroside concentration in the extracts showed no dependence on COX-2 inhibition. The extracts demonstrated a direct correlation of COX-2 inhibitory activity with their triterpenoid-/steroidal-saponin concentration. COX-2 inhibition increased linearly with the concentration of the saponins. CONCLUSION: The data suggest that Waltheria Indica extracts inhibit the key inflammatory enzyme, COX-2, as a function of triterpenoid- and steroidal-saponin concentration and support the known efficacy of extracted Waltheria Indica leaves as a traditional treatment against inflammation related diseases.